Grant provides near-term capital relief and third-party validation for APVO451. Monitor for development candidate selection announcement by year-end 2026; preclinical data releases could be catalysts. No immediate financial impact but reduces dilution risk.
Price Chart
Executive Summary
Aptevo Therapeutics secured a $1.5M non-dilutive grant from the Andy Hill CARE Fund to support IND-enabling studies for APVO451, a trispecific antibody candidate targeting nectin-4 for solid tumors. The grant provides external validation and extends the company's cash runway while advancing a key pipeline program toward candidate selection by year-end 2026.
Key Facts
- Grant of $1,499,951 from Andy Hill CARE Fund, non-dilutive, on a reimbursement basis
- Funds support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4/CD40/CD3
- Project period through June 2028; milestones include development candidate selection by year-end 2026 and IND studies in Q1 2027
- Company retains IP generated, subject to commercialization and public benefit commitments
- Matching non-state contributions required at least equal to grant amount
Financial Impact
$1.5M non-dilutive funding, ~25% of market cap at $6M, extends cash runway for preclinical development
Risk Factors
- Grant funds are reimbursable and subject to milestone achievement and matching contributions
- APVO451 is preclinical; risk of failure in IND-enabling studies
- Company has small market cap ($6M) and may need additional capital for clinical development beyond this grant
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290473 |
| Document: apvo-ex99_1.htm | 0001193125-26-290473 |
| Document: 0001193125-26-290473-index-headers.html | 0001193125-26-290473 |
| Document: 0001193125-26-290473-index.html | 0001193125-26-290473 |
| Document: 0001193125-26-290473.txt | 0001193125-26-290473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.73 | awaiting T+5 | — | $1.53 (−11.65%) |
Oct 23, 2026 2d ago | 8-K | $1.61 | awaiting T+5 | — | $1.53 (−4.97%) |
Oct 14, 2026 12d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.53 (−11.56%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.53 (−16.39%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.53 (−10.53%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.53 (+10.53%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.53 (−47.96%) |
Jul 27, 2026 12w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.53 (−63.66%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.53 (−65.62%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.53 (−68.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers